Suppr超能文献

[同步放疗与动脉内化疗治疗不可切除口腔面部肿瘤的预后因素]

[Prognostic factors in the treatment of inoperable orofacial tumors with simultaneous radiotherapy and intra-arterial chemotherapy].

作者信息

Szepesi T, Stadler B, Hohenberg G, Hollmann K, Kühböck J, Mailath G

出版信息

Strahlentherapie. 1985 May;161(5):299-307.

PMID:2408359
Abstract

Between January 1973 and April 1982 66 evaluable patients with advanced inoperable orofacial tumours underwent intraarterial Bleomycin and Methotrexate with simultaneous radiotherapy in a prospective study. 32 patients had no previous treatment, 34 patients had initial surgery, radiotherapy and/or chemotherapy. 15 mg Bleomycin were administered through a catheter into the arteria externa carotis daily in the morning. 25 mg Methotrexate were given in the same way at night followed by 3 mg Calcium-Leucovorin i.m. every 8 hours. The cumulative dose was 300 mg Bleomycin and 500 mg Methotrexate. Four hours after the administration of Bleomycin the target volume was irradiated (single fraction 2 Gy, total dose 60 to 65 Gy). The overall response rate was 65% containing 17% complete and 48% partial remission. Destruction of the bone appeared to be the most important index at the start of the therapy. Further prognostic determinants as previous treatment, localisation of the primary tumours (maxilla and mandibula respectively oral cavity and oropharynx) and local regional lymphnode stage missed statistically significance in the survival time, may be due to a possible radiosensitizing effect of the simultaneous chemotherapy. Complete remission turned out to be the most important prognostic factor after the end of treatment. Patients responding with complete remission show a median disease free survival of 56+ months and a median survival time of 82 months. Acute reactions were reversible. Only in 14% of the patients the treatment could not be finished. Better results could be obtained by electron-affinic radiosensitizers and high LET radiation.

摘要

在1973年1月至1982年4月期间,66例可评估的晚期无法手术切除的口腔颌面肿瘤患者接受了动脉内博来霉素和甲氨蝶呤联合同步放疗的前瞻性研究。32例患者此前未接受过治疗,34例患者曾接受过初始手术、放疗和/或化疗。每天上午通过导管向颈外动脉注入15毫克博来霉素。晚上以同样方式给予25毫克甲氨蝶呤,随后每8小时肌肉注射3毫克亚叶酸钙。博来霉素累积剂量为300毫克,甲氨蝶呤累积剂量为500毫克。在给予博来霉素4小时后对靶区进行照射(单次剂量2 Gy,总剂量60至65 Gy)。总缓解率为65%,其中完全缓解率为17%,部分缓解率为48%。骨破坏似乎是治疗开始时最重要的指标。其他预后决定因素,如先前的治疗、原发肿瘤的部位(分别为上颌骨和下颌骨以及口腔和口咽)和局部区域淋巴结分期,在生存时间上未显示出统计学意义,这可能是由于同步化疗可能具有放射增敏作用。治疗结束后,完全缓解被证明是最重要的预后因素。完全缓解的患者中位无病生存期为56 +个月,中位生存期为82个月。急性反应是可逆的。只有14%的患者无法完成治疗。使用亲电子放射增敏剂和高传能线密度辐射可能会获得更好的结果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验